Re: [MOL] KATHY Q./reply to Lillian/Kathy [01019] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

Re: [MOL] KATHY Q./reply to Lillian/Kathy



That's it, I had re sent it since it seemed like such good news for folks
with AML!  Terrific, glad you found it and thanks bunches for letting me
know your friend, lillian



Warmly, lillian

We invite you to take a look at our Album.
www.angelfire.com/sc/molangels/index.html

  ( Very informational, good tips, Molers pictures, art work and much
more....

----- Original Message -----
From: <Qksk@AOL.COM>
To: <mol-cancer@lists.meds.com>
Sent: Sunday, March 12, 2000 10:15 AM
Subject: Re: [MOL] KATHY Q./reply to Lillian


> Hi Lillian,
>
> When I went back through the articles I've forwarded to Tommy, I found
this
> one from you.  Is this the one you were talking about?  Thank you for
looking
> my friend...  :-))
>
> Love ya,  Kathy Q
>
>
> Subj:    [MOL] Antibody targeted chemotherapy to fight leukemia
> Date:   3/7/00 11:43:27 PM Pacific Standard Time
> From:   firefly@islc.net (Lillian)
> Sender: owner-mol-cancer@lists.meds.com
> Reply-to:   mol-cancer@lists.meds.com
> To: mol-cancer@lists.meds.com (mol)
>
> http://www.sciencedaily.com/releases/1999/05/990519065323.htm
>
>       Source:   Fred Hutchinson Cancer Research Center
> (http://www.fhcrc.org/)
>
>
>       Date:   Posted 5/19/99
>
> Breakthrough New Therapy Uses Antibody-Targeted Chemotherapy To Fight
> Leukemia
> Scientists presented promising data today at the 35th Annual Meeting of
the
> American Society of Clinical Oncology (ASCO) on the use of a pioneering
drug
> technology known as "antibody-targeted chemotherapy" to fight acute
> myelogenous leukemia (AML) - a virulent and often fatal form of cancer.
The
> experimental agent, CMA-676, induces remission in a significant proportion
of
> patients with few serious side effects. CMA-676 represents the first
> successful application of antibody-targeted chemotherapy.
> AML is an aggressive, life-threatening disease in which certain white
blood
> cells become cancerous and rapidly replace normal bone marrow and blood
> cells. AML is among the most serious forms of adult leukemia, with a
> relatively high fatality rate. Most patients require intensive
chemotherapy
> to achieve complete remission, and some also must undergo bone marrow
> transplants. Up to half of patients with AML, even after such intensive
> treatment, have residual leukemic cells or experience a relapse.
>
> Because current chemotherapy drugs to treat AML are non-specific -
destroying
> good as well as bad cells - patients receiving standard chemotherapy tend
to
> become very sick. Researchers at the Fred Hutchinson Cancer Research
Center,
> in collaboration with scientists from thirteen leading leukemia centers,
> including University of Chicago Medical Center, MD Anderson Cancer Center,
> and the University of Pennsylvania Cancer Center, are working with
> Wyeth-Ayerst Research and Celltech PLC to study CMA-676, an antibody-drug
> conjugate that delivers treatment directly to the leukemia cells.
>
> The specificity of the conjugate lies in the antibody, which recognizes a
> cell-surface molecule that is abundant on AML cells. Importantly, however,
> the cell surface molecule is absent from normal blood stem cells, the
seeds
> from which normal blood and immune cells originate. Specially engineered
to
> carry a novel and extremely potent chemotherapy agent known as
calicheamicin,
> the antibody selectively targets leukemic blast cells, while sparing cells
> that are responsible for replenishing normal blood cells once the leukemia
is
> eradicated.
>
> Promising results continue to emerge from a pivotal Phase II trial in the
> U.S., which involves patients who experienced a relapse following initial
AML
> chemotherapy. CMA-676 given alone appears to produce remission among 36
> percent of patients- a rate comparable to that of standard combination
> chemotherapy regimens. The data also indicate that CMA-676 has several
> important advantages over standard agents.
>
> "The side effects are mild and well-tolerated relative to standard
> chemotherapy, especially by elderly patients," says Eric Sievers, M.D., of
> Fred Hutchinson Cancer Research Center. "Also, the treatment did not
produce
> some of the more common chemotherapy-induced side effects."
>
> Whereas standard combination chemotherapy treatment often produces
> significant major organ damage, and sores both in the mouth and in the
> intestinal tract (frequent sources for opportunistic infections), CMA-676
> treatment does not. CMA-676 also is associated with a relatively low
> treatment-related mortality. As with standard chemotherapy treatments,
> CMA-676 produces a temporary suppression of bone marrow and blood cell
> counts.
>
> CMA-676 is administered in two IV infusions fourteen days apart, and many
> patients have received the drug on an outpatient basis. Unlike standard
> chemotherapy regimens, which involve multiple drugs, CMA-676 is given
alone.
> It is thus less likely to produce serious drug-drug interactions.
>
> Similar studies of this new therapy are underway throughout Europe and
> Canada, and the developers of CMA-676 eventually hope to adapt their
> groundbreaking technology for the treatment of other devastating cancers.
>
>
> ### The Fred Hutchinson Cancer Research Center is an independent,
non-profit
> research institution dedicated to the development and advancement of
> biomedical technology to eliminate cancer and other potentially fatal
> diseases. Recognized internationally for its pioneering work in bone
marrow
> transplantation, the Center has four scientific divisions collaborating to
> form a unique environment for conducting basic and applied science. One of
35
> National Cancer Institute-designated comprehensive cancer centers in the
> country, it is the only one in the Northwest. Visit the Hutchinson Center
web
> site for more information at http://www.fhcrc.org.
>
>
>
> --------------------------------------------------------------------------
----
> --
>
> Note: This story has been adapted from a news release issued by Fred
> Hutchinson Cancer Research Center for journalists and other members of the
> public. If you wish to quote from any part of this story, please credit
Fred
> Hutchinson Cancer Research Center as the original source. You may also
wish
> to include the following link in any citation:
> ------------------------------------------------------------------------
> This is an automatically-generated notice.  If you'd like to be removed
> from the mailing list, please visit the Medicine-On-Line Discussion Forum
> at <http://www.meds.com/con_faq.html>, or send an email message to:
> majordomo@lists.meds.com
> with the subject line blank and the body of the message containing the
line:
> unsubscribe mol-cancer your-email-address
> where the phrase your-email-address is replaced with your actual email
> address.
> ------------------------------------------------------------------------
>

------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------